Express Scripts sees slow 2016 sales for new cholesterol drugs

NEW YORK, Feb 12 (Reuters) - A surge in sales of pricey new cholesterol treatments is unlikely to materialize this year, contrary to the previous expectations of Express Scripts Holding , an executive from the largest manager of U.S. drug benefits said on Friday.